Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein |
| |
Authors: | Koren E De Groot A S Jawa V Beck K D Boone T Rivera D Li L Mytych D Koscec M Weeraratne D Swanson S Martin W |
| |
Institution: | Scios Inc., 6500 Paseo Padre Pkway, Fremont, CA 94555, USA. ifica99@yahoo.com |
| |
Abstract: | Antibodies elicited by protein therapeutics can cause serious side effects in humans. We studied immunogenicity of a recombinant fusion protein (FPX) consisting of two identical, biologically active, peptides attached to human Fc fragment. EpiMatrix, an in silico epitope-mapping tool, predicted promiscuous T-cell epitope(s) within the 14-amino-acid carboxy-terminal region of the peptide portion of FPX. On administration of FPX in 76 healthy human subjects, 37% developed antibodies after a single injection. A memory T-cell response against the above carboxy-terminus of the peptide was observed in antibody-positive but not in antibody-negative subjects. Promiscuity of the predicted T-cell epitope(s) was confirmed by representation of all common HLA alleles in antibody-positive subjects. As predicted by EpiMatrix, HLA haplotype DRB1*0701/1501 was associated with the highest T-cell and antibody response. In conclusion, in silico prediction can be successfully used to identify Class II restricted T-cell epitopes within therapeutic proteins and predict immunogenicity thereof in humans. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|